Cancer Treatment ETF, Anyone? Q&A with a Top Biotech Investor

We recently had the opportunity to talk to Brad Loncar, CEO of Loncar Investments. He is a top biotech investor and just launched a new ETF; the Loncar Cancer Immunotherapy ETF ( CNCR ) tracks the performance of biotech equities. The primary business of the equities in this ETF is finding treatments for cancer through immunotherapy.